Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4040776 | 1.00 | PREP (0.39) | PREPMEN1KMT2ATDP1CHRM2 | |
| SCHEMBL993595 | 1.00 | PREP (0.39) | PREPMEN1KMT2ATDP1CHRM2 | |
| SCHEMBL4663681 | 1.00 | PREP (0.39) | PREPMEN1KMT2ATDP1CHRM2 | |
| SCHEMBL4039208 | 0.86 | PREP (0.38) | PREPMEN1KMT2ATDP1CHRM2 | |
| SCHEMBL19083691 | 0.84 | PREP (0.40) | PREPMEN1KMT2ATDP1CHRM2 | |
| SCHEMBL27207857 | 0.80 | PREP (0.35) | PREP | |
| SCHEMBL19075578 | 0.80 | PREP (0.43) | PREPMEN1KMT2ATDP1CHRM2 | |
| SCHEMBL19075817 | 0.80 | PREP (0.43) | PREPMEN1KMT2ATDP1CHRM2 | |
| SCHEMBL11153522 | 0.78 | PREP (0.44) | PREPMEN1KMT2AAGTR2 | |
| SCHEMBL18829248 | 0.77 | TDP1 (0.46) | PREPMEN1KMT2ATDP1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-11878965-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-01-23 | — | — | US | disclosed |
| EP-4267587-A2 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | Gilead Sciences, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4267562-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230090053-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-03-23 | — | — | US | disclosed |
| EP-4143189-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20220227787-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2022-07-21 | — | — | US | disclosed |
| WO-2022140390-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140428-A2 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230090053-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | PREP 453/4885MEN1 2517/4885KMT2A 1652/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | PREP 1910/4885MEN1 348/4885KMT2A 2081/4885 |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | PREP 453/4885MEN1 2517/4885KMT2A 1652/4885 |
| US-20220227787-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | PREP 482/4885MEN1 2927/4885KMT2A 1657/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | PREP 1910/4885MEN1 348/4885KMT2A 2081/4885 |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | PREP 453/4885MEN1 2517/4885KMT2A 1652/4885 |
| US-11878965-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | PREP 453/4885MEN1 2517/4885KMT2A 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.